TNFRSF8 expression

BV is a key therapy for CD30-positive CTCL. While real-world experience suggests potential activity in CD30-negative or low disease, prospective trials are needed to define its role in this challenging subgroup.

P1/2, N=40, Recruiting, Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau | Not yet recruiting --> Recruiting

Treatment with brentuximab vedotin yielded early alleviation of pruritus and progressive resolution of lesions by the third cycle, with favorable tolerability. This case serves as a foundation for a narrative review that underscores the diagnostic challenges associated with "allergic-appearing" eruptions in patients with T-cell lymphoma, the importance of integrated staging utilizing TNMB (skin/blood) in conjunction with Lugano/Deauville positron emission tomography-computed tomography to assess systemic burden and therapeutic response, and biologically informed systemic therapy options aligned with comorbidities, including emerging targeted treatment strategies.

Collectively, these findings demonstrate that CD30L critically regulates asthma airway remodeling via the JNK/p38 MAPK pathway, strongly suggesting its therapeutic potential as a target for airway remodeling in asthma.

One patient was known to decease despite chemotherapy. In conclusion, oral manifestations of ALCL are very rare and more commonly represent a disseminated disease.

An analysis of early phase clinical trial data reveals encouraging efficacy, with high rates of durable complete responses observed even in heavily pretreated patients who have failed brentuximab vedotin therapy...While these findings are promising, it is essential to acknowledge that the current evidence base remains preliminary, derived from small, heterogeneous patient cohorts and requiring validation in larger, more definitive trials with extended follow-up. By successfully addressing the challenge of fratricide, anti-CD30 CAR-T therapy holds the potential to become a transformative and potentially curative option for patients with R/R ALCL and may offer a valuable blueprint for developing effective immunotherapies against other T-cell malignancies.

P2, N=55, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

Collectively, the morphology, phenotype, and genotype of HRS cells reveal a complex pathogenic network in which intrinsic oncogenic pathways and extrinsic TME interactions co-operate to sustain malignant transformation. Understanding these integrated mechanisms provides a biological foundation for current therapeutic strategies.

P1, N=58, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns

P1, N=0, Withdrawn, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | N=18 --> 0 | Recruiting --> Withdrawn

P1, N=57, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Completed --> Active, not recruiting